



EGFR Antibody (Center R858) Blocking Peptide

Synthetic peptide Catalog # BP7628d

Specification

EGFR Antibody (Center R858) Blocking Peptide - Product Information

Primary Accession P00533
Other Accession EGFR HUMAN

EGFR Antibody (Center R858) Blocking Peptide - Additional Information

Gene ID 1956

Other Names

Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1. HER1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP7628d was selected from the center region with arginine at 858th position of human EGFR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

EGFR Antibody (Center R858) Blocking Peptide - Protein Information

EGFR Antibody (Center R858) Blocking Peptide - Background

EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

EGFR Antibody (Center R858) Blocking Peptide - References

Aifa, S., et al., Exp. Cell Res. 302(1):108-114 (2005).Adams, T.E., et al., Growth Factors 22(2):89-95 (2004).Ichinose, J., et al., Biochem. Biophys. Res. Commun. 324(3):1143-1149 (2004).Kuribayashi, A., et al., Endocrinology 145(11):4976-4984 (2004).Kapoor, G.S., et al., Mol. Cell. Biol. 24(2):823-836 (2004).



Name EGFR (HGNC:3236)

Synonyms ERBB, ERBB1, HER1

Function

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:<a href="http://www.uniprot.org/c itations/2790960"

target="_blank">2790960,

PubMed: <a href="http://www.uniprot.org/ci tations/10805725"

target="_blank">10805725,

PubMed:<a href="http://www.uniprot.org/ci tations/27153536"

target="_blank">27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin,

epiregulin/EREG and HBEGF/heparin-

binding EGF (PubMed:<a href="http://www.uniprot.org/citations/2790960"

target="_blank">2790960,

PubMed:<a href="http://www.uniprot.org/ci tations/7679104"

target=" blank">7679104,

PubMed: <a href="http://www.uniprot.org/ci tations/8144591"

target=" blank">8144591,

PubMed: <a href="http://www.uniprot.org/ci tations/9419975"

target=" blank">9419975,

PubMed:<a href="http://www.uniprot.org/ci tations/15611079"

target=" blank">15611079,

PubMed:<a href="http://www.uniprot.org/ci tations/12297049"

target=" blank">12297049,

PubMed:<a href="http://www.uniprot.org/ci tations/27153536"

target=" blank">27153536,

PubMed:<a href="http://www.uniprot.org/ci tations/20837704"

target="_blank">20837704,

PubMed: <a href="http://www.uniprot.org/ci tations/17909029"

target="_blank">17909029). Ligand binding triggers receptor homo- and/or heterodimerization and

autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades

including the RAS-RAF-MEK-ERK, PI3



kinase-AKT, PLCgamma-PKC and STATs modules (PubMed: 27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:<a hr ef="http://www.uniprot.org/citations/20462 955" target=" blank">20462955). Plays a role in enhancing learning and memory performance (By similarity).


Cellular Location

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein Endosome Endosome membrane. Nucleus. Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546, PubMed:17909029). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536, PubMed:17909029). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055)

Tissue Location

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

EGFR Antibody (Center R858) Blocking Peptide - Protocols





Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides